SANTA ROSA BEACH, Fla. and SINGAPORE, Oct. 10, 2023 /PRNewswire/ -- Fibronostics, a global leader in non-invasive, AI-driven diagnostic testing for *MAFLD/MASH patients, announced today a strategic partnership with Stone Diagnostics, a leading provider of laboratory services in the United States.  Stone Diagnostics will provide Physicians and their patients end to end service to enable Physicians to assess chronic liver disease with Fibronostics' benchmark product, LIVERFASt™.  Stone Diagnostics' combination of scaled operational excellence and leading digital capabilities leveraging MyHealthAI is ideal and vital to serve doctors using LIVERFASt™ to screen, identify and monitor *MAFLD/MASH patients. .

佛罗里达州圣罗莎海滩和新加坡，2023年10月10日/PRNewswire/-Fibronostics，一家针对*MAFLD/MASH患者的非侵入性，AI驱动诊断测试的全球领导者，今天宣布与Stone Diagnostics建立战略合作伙伴关系，美国领先的实验室服务提供商。Stone Diagnostics将为医生及其患者提供端到端服务，使医生能够使用Fibronostics的基准产品LIVERFASt评估慢性肝病™.Stone Diagnostics利用MyHealthAI将规模卓越的运营和领先的数字功能相结合，对于使用LIVERFASt为医生提供服务是理想且至关重要的™筛选，识别和监测*MAFLD/MASH患者。 .

'We are delighted to partner with Stone Diagnostics to provide LIVERFASt™ to the medical community', said Fibronostics CEO Sven Henrichwark. 'Liver disease has historically required more invasive procedures such as biopsies. Recent guideline updates from AASLD and EASL recognize biopsy drawbacks and acknowledge that non-invasive methods such as LIVERFASt™ can identify advanced fibrosis in patients more effectively and with a higher level of confidence.

'我们很高兴与Stone Diagnostics合作提供LIVERFASt™Fibronostics首席执行官Sven Henrichwark说历史上，肝病需要更多侵入性手术，例如活组织检查。AASLD和EASL最近的指南更新认识到活检的缺点，并承认像LIVERFASt这样的非侵入性方法™可以更有效地识别患者的晚期纤维化并具有更高的信心。

Providing the thousands of Physicians who manage the millions of adult Americans with chronic Liver Disease access to our benchmark AI-based test, LIVERFASt™, demands the consistent, high-quality service that Stone exemplifies.'.

为成千上万管理数百万患有慢性肝病的成年美国人的医生提供我们基于AI的基准测试LIVERFASt™,要求石头所体现的一致，高质量的服务。”。

Brock Smith, Fibronostics GM for the Americas added, 'our strategic partnership with Stone Diagnostics gives us the comprehensive, efficient, reproducible, and scalable Laboratory Operations Platform required to meet increasing LIVERFASt™ demand and allows us to focus on the most important needs of our Prescribers and their Patients.

Brock Smith，美国Fibronostics GM补充说，“我们与Stone Diagnostics的战略合作关系为我们提供了满足日益增长的LIVERFASt所需的全面，高效，可重复和可扩展的实验室操作平台™需求并允许我们关注处方者及其患者的最重要需求。

Our mission is to deliver Best-In-Class AI-driven Medical Technology and Customer Support to our Customers and their Patients, and this partnership with Stone will position us to do just that.'.

我们的使命是为客户及其患者提供一流的AI驱动医疗技术和客户支持，与Stone的这种合作将使我们能够做到这一点。

'Stone Diagnostics is a market leading group of in-network diagnostic companies located in New Orleans LA, Santa Rosa Beach FL and Atlanta GA' said Christopher Ridgeway, Founder and CEO.  'Today, we are extremely excited about partnering with Fibronostics. This partnership will aligns well with Stone's focused future in the AI space.

创始人兼首席执行官克里斯托弗·里奇韦（Christopher Ridgeway）说：“Stone Diagnostics是位于新奥尔良洛杉矶，圣罗莎海滩佛罗里达州和亚特兰大GA的市场领先的网络诊断公司集团。“今天，我们对与Fibronostics合作非常兴奋。这种合作关系将与Stone在人工智能领域的重点未来保持一致。

Integrating AI technology within the Healthcare market dovetails perfectly into our own AI platform (MyHealthAI- myhealthai.org) and strategy. This differentiates our company in the diagnostics market bringing tremendous growth to our chemistry and hematology platforms. We believe that our high focus on customer service and our ability to execute with speed and operational excellence will continue to drive significant growth and further differentiate Stone from other diagnostic companies.'.

将AI技术整合到医疗保健市场中，完美地融入我们自己的AI平台（MyHealthAI-MyHealthAI.org）和战略。这使我们在诊断市场的公司与众不同，为我们的化学和血液学平台带来了巨大的增长。我们相信，我们高度关注客户服务以及我们以快速和卓越运营执行的能力将继续推动显着增长，并进一步将石材与其他诊断公司区分开来。

Fibronostics is a global diagnostics company, providing non-invasive testing and insights to detect and manage organ lesions caused by metabolic diseases such as *MAFLD/MASH. The company leverages artificial intelligence to screen for liver and kidney disease, as well as other chronic conditions that cause progressive organ damage.

Fibronostics是一家全球诊断公司，提供非侵入性测试和见解，以检测和管理由代谢性疾病引起的器官病变，如*MAFLD/MASH。该公司利用人工智能筛查肝脏和肾脏疾病，以及导致进行性器官损害的其他慢性病。

Its lead product, LIVERFASt, is a neural network driven AI technology combining anthropometrics with broadly available biomarkers from a single blood draw. LIVERFASt™ provides insights of high clinical relevance about the degree of fibrosis, steatosis and activity a patient's liver has. The test uniquely combines the ease of use and clinical sensitivity needed to do the large-scale testing which is crucial for the effective identification and monitoring of a high prevalence condition such as *MAFLD/MASH.

其领先产品LIVERFASt是一种神经网络驱动的人工智能技术，将人体测量学与单次抽血中广泛可用的生物标志物相结合。LIVERFASt™提供有关患者肝脏纤维化程度，脂肪变性和活动程度的高度临床相关性的见解。该测试独特地结合了进行大规模测试所需的易用性和临床敏感性，这对于有效识别和监测高流行状况（例如*MAFLD/MASH）至关重要。

MAFLD has a prevalence of 20-24% in the adult population of the United States..

MAFLD在美国成年人口中的患病率为20-24%。。

*MAFLD/MASH https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10029949/

*MAFLD/MASH https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10029949/

SOURCE Fibronostics

来源Fibronostics